The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > REGULATORY
REGULATORY
- LDP Lawmakers Air Concerns over MOF Push for Negative Fee Revision
November 8, 2023
- Abecma Clears Japan Panel Review for 3rd Line MM Use
November 7, 2023
- Health Minister to Make Direct Request to 24 Makers for Supply Ramp-Up
November 7, 2023
- Japan PM Advisor Pushes Rethink of LLP Coverage to Reward Innovation, Pricing Debate without Taboos
November 6, 2023
- Japan OKs New Economic Package; Startup, Pharma Promotion Embraced
November 6, 2023
- FPMAJ Renews Call for Premium for Drugs Launched in Japan without Delay: LDP Confab
November 6, 2023
- Reward Innovation by Revisiting LLP Copay, Cut Doctor Fees: MOF
November 2, 2023
- Japan PM Pins Hope for Leadership of Kamoshita as Drug Policy Advisor
November 2, 2023
- MHLW to Consider Investigation on OTC Drug Abuse: Minister
November 2, 2023
- Organization to Push Drug Discovery Is One Option: Health Minister
November 1, 2023
- Basic Dementia Law Set to Take Effect on January 1: MHLW
November 1, 2023
- Japan Economic Package to Call for Boosting Innovation for Next-Gen Biologics
November 1, 2023
- Cases of Unintentional Xocova Use in Pregnant Women Total 32: MHLW
October 31, 2023
- AMED, Europe’s HERA to Cooperate in Medical Countermeasures
October 31, 2023
- PMDA Investigating Safety Risks of Eliquis, Other Anticoagulants for Acute Kidney Injury
October 30, 2023
- No Objections to Reflecting Company Indices for Generic Supplies in Pricing: Chuikyo
October 30, 2023
- Medical, Long-Term Care Data Linkage Holds Key to CEA: Leqembi Debate
October 30, 2023
- Panel OKs Xarelto’s Label Expansion for Post-Fontan Heart Failure Patients
October 30, 2023
- Lawmakers Demand NIP Coverage for Male Use of 4-Valent HPV Vaccine
October 26, 2023
- Japan’s Healthcare Spending Hits 45 Trillion Yen in FY2021
October 26, 2023
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…